S_ry A 95 kDa membrane protein (P-95) has been previously noted to be overexpr in a doxorubicin-resistant subie of the MCF-7 breast cancer line and in cinical samples obtained from patients with soLid tumours refractory to doxorubcin. We performed Western blotting on blast cell lysates from adults with acute myeloid Leukacmia, using The development of drug resistance in leukaemia cells constitutes the major reason for treatment failure in patients with acute myeloid leukaemia (AML). The mainstays of treatment of AML are the antimetabolite cytarabine and a variety of natural product drugs, including the anthracycline daunorubicin (dnr), the anthraquinone mitoxantrone and the epipodophyllotoxin etoposide. During the past decade, cellular resistance to a broad spectrum of unrelated natural cytotoxins has been described in leukaemia and other neoplasms and has been termed multidrug resistance (MDR) (Rothenburg and Ling, 1989). The classic pattern of MDR has been associated with the overexpression of P-glycoprotein (Pgp), the 170 kDa product of the MDR] gene (Juliano and Ling, 1976) . Pgp is thought to function as an energydependent efflux pump for a variety of molecules, including certain chemotherapeutic agents (Fojo et al., 1985) . The role of Pgp in mediating MDR in leukaemia remains unclear. Several studies, using slot-blot hybridisation for mdrl message, or immunohistochemical or flow cytometric detection of Pgp with the MRK16 or C219 monoclonal antibodi, have found a high frequency (>30% of patient samples) of reactivity with these probes in AML blasts at the time of presentation (Sato et al., 1990; Marie et al., 1991) . Other studies, including our own, found a low frequency of MDR] expression in AML cells from previously untreated patients (Ito et al., 1989; Kato et al., 1991; Ross et al., 1993 (Ross et al., 1993) . This discrepancy between the presence of a drug efflux pump and the absence of detectable Pgp suggests that other anisMs of drug efflux may be present.
The development of drug resistance in leukaemia cells constitutes the major reason for treatment failure in patients with acute myeloid leukaemia (AML). The mainstays of treatment of AML are the antimetabolite cytarabine and a variety of natural product drugs, including the anthracycline daunorubicin (dnr), the anthraquinone mitoxantrone and the epipodophyllotoxin etoposide. During the past decade, cellular resistance to a broad spectrum of unrelated natural cytotoxins has been described in leukaemia and other neoplasms and has been termed multidrug resistance (MDR) (Rothenburg and Ling, 1989) . The classic pattern of MDR has been associated with the overexpression of P-glycoprotein (Pgp), the 170 kDa product of the MDR] gene (Juliano and Ling, 1976) . Pgp is thought to function as an energydependent efflux pump for a variety of molecules, including certain chemotherapeutic agents (Fojo et al., 1985) .
The role of Pgp in mediating MDR in leukaemia remains unclear. Several studies, using slot-blot hybridisation for mdrl message, or immunohistochemical or flow cytometric detection of Pgp with the MRK16 or C219 monoclonal antibodi, have found a high frequency (>30% of patient samples) of reactivity with these probes in AML blasts at the time of presentation (Sato et al., 1990; Marie et al., 1991) . Other studies, including our own, found a low frequency of MDR] expression in AML cells from previously untreated patients (Ito et al., 1989; Kato et al., 1991; Ross et al., 1993) . In another series of 56 patients, no detectable Pgp was observed by filter hybridisation, whereas 27 of the 51 had a low level expression of MDR] detected by reverse transcriptase-polymerase chain reaction (Noonan et al., 1991) . These low levels of MDRJ expression did not correlate with the clinical response of the leukaemia patients to chemotherapy.
We have noted variability of dnr uptake and retention in leukaemic blast cells from different patients. In our studies, the MDR modulators cyclosporin A (CsA) and verapamil caused statistically significant enhancement of dnr accumulation, retention and cytotoxicity in more than half of marrow Correspondence: LA al., 1993) . The results of these functional assays for facilitated dnr export contrast with our observation of detectable Pgp expression in less than 10% of our AML bone marrow samples using a sensitive Western blot assay (Ross et al., 1993) . This discrepancy between the presence of a drug efflux pump and the absence of detectable Pgp suggests that other anisMs of drug efflux may be present.
In addition to Pgp, recent studies suggest that other cellsurface proteins might contribute to MDR in certain cell types (Marquardt et al., 1990; Cole et al., 1992) . A novel 95 kDa MDR-associated membrane protein, termed P-95, has been reported to be overexpressed in MCF-7 breast cancer cells selected for resistance to doxorubicin in the presence of verapamiL in order to inhibit the development of Pgp overexpression (Chen et al., 1990) . The resistant subline, termed MCF-7/AdrVp, does not express Pgp, and is highly resistant to anthracyclines, melphalan and VM-26, but not vinblastine. Glutathione content and the activity of the glutathione transferases were not alterd and depletion of glutathione with buthionine sulphoxime did not affect drug resistance. Prolonged culture of MCF-7/AdrVp cells in drug-free medium led to the development of drug-sensitive revertants, which were noted to have greatly diminished expression of P-95. Immunohistochemical and indirect immunofluorescence experiments demonstrated localisation of the P-95 protein on the cell surface, and the protein was enriched in detergentsolubiised membrane fractions of MCF-7/AdrVp. The demonstration of P-95 protein in biopsy specimens from solid tumour patients refractory to chemotherapy suggested that the protein might play a role in clinical drug resistance (Chen et al., 1990) .
We recently reported that P-95 was highly expressed in two human small-cell lung cancer cell lines, NCI-H1688 and NCI-H660, that displayed intrinsic multidrug resistance (Doyle et al., 1993) . These cell lines do not overexpress Pgp or the recently described multidrug resistance protein (MRP), and have an atypical pattern of drug resistance (Cole et al., 1992; Doyle et al., 1993) . We now report studies of P-95 Daunorubicin accwnuation and retention studies These studies were performed solely from patients at our institution, as previously described (Ross et al., 1993) . AML blast cells, from 46 marrow specmens, were exposed in culture (RPMI-1640 medium, 10% fetal calf serum, pH 7.2) to dnr (1 &g ml-') for 3 h, which we have noted was the time required for blast cells to achieve intracellular steady-state levels of dnr (Ross et al., 1986 Figure 1 . In this blot, we considered patient sample MR, AM, FR, GP and LT to be positive for P-95 expression.
Twenty-nine patients were tudied at the time of diagnosis, of which 10/29 (34%) were P-95 positive. Seven bone marrow samples from six of these patients were also obtained at relapse. Of the six patients with marrows obtained both at diagnosis and after treatment, two demonstrated P-95 expression to be increased in the relapsed specimen relative to the initial marrow sample. For example, one patient (MR) had undetectable P-95 expression at diagosis (Figure 1 , lane 16 from left), but had readily detectable expresson of the protein at different relapse marrows (Figure 1, lanes 6 and 12) .
In the other four paired specimens, P-95 expression was essentially unchanged between the times of diagnosis and relapse.
Ten AML patients had samples obtained for P-95 studies only at the time of relapse. Of these ten relapsed patients, Correlation of P-95 Western blotting with dnr accwnulation and retention Concomitant flow cytometric assays measuring 3 h accumulation of dnr (1 jig ml-') were performed on AML blast cells from the 46 patient marrows used for P-95 Western blotting. Sixteen of these 46 samples were positive for P-95 expression by Western blotting. Thirty-seven of the 46 samples also had flow cytometric assays of dnr retention performed 16 h after washing the blast samples free of extracellular drug. Of the 37 marrow samples tested for dnr retention, 13 were positive for P-95 by Western blotting.
The P-95-positive marrows had reduced accumulation of dnr relative to the negative marrows (Figure 2 ). The difference was statistically significant using a Mann-Whitney test, with P = 0.033. Only one of the P-95-positive samples had an accumulation value greater than the median of the P-95-negative samples. A trend was also noted for decreased dnr retention in the P-95-positive marrows (Figure 2) , with P = 0.067. There were no P-95-positive samples with high retention of daunorubicin.
All of the AML marrows described above had dnr accumulation and retention measurements performed with or without the addition of 5 giM cyclosporin A. Forty-three samples (27 P-95-negative, 16 P-95-positive) also had dnr accumulation experiments performed with or without the addition of 6.6 pM verapamil. Thirty-four samples (21 P-95-negative and 13 P-95-positive) had dnr retention experiments performed with or without verapamil. No and retention experiments in MCF-7 cells and in the MDR subline MCF-7/AdrVp, which overexpresses P-95 ( Figure 3 ). An alteration in overall intracellular drug transport had not been previously reported in MCF-7/AdrVp cells. Both cell lines had measurements of dnr content for up to 3 h after being placed in 1 gig ml1-of the drug. As shown in Figure 3 , the accumulation of dnr reached a plateau in both lines by 3 h, but the intracellular dnr content of the resistant MCF-7/ AdrVp cells was far less than that of the sensitive parent cells. After washing the cells to remove extracellular dnr at 3 h, the retention of dnr at various time points was measured. As shown in Figure 3 , the P-95-positive MCF-7/ AdrVp cells rapidly lost almost all detectable dnr fluorescence. The sensitive MCF-7 cells, starting from a higher plateau of accumulated dnr, also showed a loss of dnr fluorescence after washing the cells free of extracellular drug, but the MCF-7 cells retain approximately 40% of the accumulated dnr 2 h after the wash. The alteration in drug accumulation observed was not due to differences in cell size between the sensitive and drug-resistant sublines. Coulter volumes were found to be 2,468 ± 116 gim3 for MCF-7/ AdrVp and 2,683 ± 100 iLm3 for MCF-7 cells. A small but consistent enhancement of dnr accumulation by cyclosporin A was noted in the P-95-positive MCF-7/ AdrVp subline (Figure 4) . No enhancement of dnr accumulation by cyclosporin A was noted in the drug-sensitive MCF-7 parent line. The approximate 40% enhancement of dnr accumulation was noted at 3 gM cyclosporin A, and was maintained at concentrations between 3 and 30 gM.
Correlation of P-95 expression with dnr cytotoxicity Forty-one AML blast samples were examined for both P-95 expression and in vitro sensitivity to dnr. Western blot analysis demonstrated 26 of these samples to be P-95 negative and 15 to be P-95 positive. No statistically significant difference, overall, was found between P-95-positive and P-95-negative samples with respect to dnr cytotoxicity ( Figure 5 ), although the difference in median cell survival between P-95-positive and -negative samples exposed to 1.0 giM dnr reaches statistical significance, with P = 0.05.
The same 41 AML marrow specimens were also tested for dnr cytotoxicity in the presence of 5 gM cyclosporin A or 6.6 gLM verapamil. Greater than 40% enhancement of dnr cell kiUing by either cyclosporin A or verapamil had previously been observed in more than 60% of the samples studied (Ross et al., 1993) . No significant difference in enhancement of dnr cytotoxicity with either modulator between the P-95-positive and -negative groups was noted.
Western blottingfor Pgp Thirty-four AML marrow lysates, from 25 patients, for which P-95 Western blotting was performed, also had immunoblotting performed for Pgp with the C219 monoclonal antibody (Ross et al., 1993 Lysates from the multidrug-resistant lung cancer line NCI-H1688, hybridised with the P-95 antisera, also had a crossreacting high molecular weight bands of unknown significance, as shown in Figure 1 . This high molecular weight band in NCI-H1688, but not MCF-7 AdrVp, is demonstrable in three different antisera against P-95, generated against either MCF-7 AdrVp or NCI-H1688 membranes. The high molecular weight protein does not appear to be P-glycoprotein or MRP since the genes encoding these proteins are not detectably overexpressed in NCI-H 1688 or MCF-7 AdrVp cells by reverse transcriptase PCR assays. A lack of total specificity of the P-95 antisera is not surprising, since the gel-purified 95 kDa band is the best current immunogen. but the 95 kDa band by Western blotting can reliably distinguish the drug-resistant cell lines NCI-H1688 and MCF-7 AdrVp from drug-sensitive MCF-7 cells.
In AML, at present, we have not seen an obvious correlation between P-95 expression and clinical response to initial induction chemotherapy, but this may be because of the small number of patients, tumour heterogeneity, the contribution of cytarabine to the regimen and the possible contribution of other mechanisms of resistance such as those described above. Based on the association of P-95 expression with decreased accumulation of daunorubicin in AML cells, however, we feel that P-95 may have a role as a mediator of anthracycline resistance in some AML cells.
The association of P-95 with decreased dnr retention, as well as accumulation, and the small modulatory effects of CsA are more obvious in the MCF-7/AdrVp subline than in AML blasts. These differences may be due to the difficulties in comparing a subcloned cell line, made drug resistant in vitro, with a heterogeneous population of unselected leukaemia cells in a clinical specimen. Immunohistochemical studies have shown tremendous heterogeneity of P-glycoprotein and topoisomerase II expression in AML blasts (Kaufman et al., 1994) . It is very likely that AML samples that are positive for P-95 by Western blotting will still have a large proportion of cells that do not express the protein.
More convincing evidence for the role of P-95 as a drug resistance protein will require cloning of the cDNA encoding P-95 and demonstrating decreased anthracycline accumulation and drug resistance in cells that have been transfected with the cDNA.
